Understanding transporter-mediated drug–drug interactions (DDIs) for investigational
agents is important during drug development to assess DDI liability, its clinical relevance …

Membrane transport proteins are involved in the absorption, disposition, efficacy, and/or
toxicity of many drugs. Numerous mechanisms (eg, nuclear receptors, epigenetic gene …

Computational pharmacology and chemistry of drug-like properties along with
pharmacokinetic studies have made it more amenable to decide or predict a potential drug …

Because of the high research and development cost of new drugs, the long development
process of new drugs, and the high failure rate at later stages, combining past drugs has …

Pharmacokinetic drug–drug interactions (DDIs) occur when a drug alters the absorption,
transport, distribution, metabolism or excretion of a co-administered agent. The occurrence …

Poor pharmacokinetic and safety profiles create significant hurdles in the drug development
process. This work focuses on a detailed understanding of drug discovery interplay among …

There is an increasing interest in transporter induction (ie, decreased systemic drug
exposure due to increased efflux‐limited absorption or transporter‐mediated clearance) as a …

Renal impairment (RI) is known to influence the pharmacokinetics of nonrenally eliminated
drugs, although the mechanism and clinical impact is poorly understood. We assessed the …

The effect of membrane transporters on drug disposition, efficacy and safety is now well
recognized. Since the initial publication from the International Transporter Consortium …

Abstract P‐glycoprotein (P‐gp) is an efflux transporter that plays an important role in the
pharmacokinetics of its substrate, and P‐gp activities can be altered by induction and …